|
rs2228570
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, TT carriers of rs2228570 were closely associated with a poor response to treatment and a higher risk of myelodysplastic syndrome/acute leukemia transformation, while CT carriers more easily evolved to overt paroxysmal nocturnal hemoglobinuria.
|
27018192 |
2016 |
|
rs2267437
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the rs228593, rs2267437 and rs1805388 functional polymorphisms probably alter the level of expression of the ATM, XRCC6 and LIG4 genes, respectively, being important in the maintenance of genomic instability in MDS.
|
27497341 |
2016 |
|
rs228593
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the rs228593, rs2267437 and rs1805388 functional polymorphisms probably alter the level of expression of the ATM, XRCC6 and LIG4 genes, respectively, being important in the maintenance of genomic instability in MDS.
|
27497341 |
2016 |
|
rs243865
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs25489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggests that XRCC1 (Arg280His) and XPD polymorphisms are associated with risk of MDS and XRCC1 polymorphism strongly associated with advanced MDS subgroup.
|
26482462 |
2016 |
|
rs3918242
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs4898
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs4898
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs745564626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggests that XRCC1 (Arg280His) and XPD polymorphisms are associated with risk of MDS and XRCC1 polymorphism strongly associated with advanced MDS subgroup.
|
26482462 |
2016 |
|
rs755174338
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggests that XRCC1 (Arg280His) and XPD polymorphisms are associated with risk of MDS and XRCC1 polymorphism strongly associated with advanced MDS subgroup.
|
26482462 |
2016 |
|
rs767232094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs8179090
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML.
|
27039800 |
2016 |
|
rs1464681682
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We previously identified missense mutations in the U2AF1 splicing factor affecting codons S34 (S34F and S34Y) or Q157 (Q157R and Q157P) in 11% of the patients with de novo myelodysplastic syndrome (MDS).
|
25311244 |
2015 |
|
rs1801320
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The G/C heterozygote genotype of rs1801320 polymorphism was associated with a decreased chance of developing MDS (p = 0.05).
|
25312513 |
2015 |
|
rs3835
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the A/G heterozygous genotype of the rs3835 polymorphism is associated with decreased chance of developing MDS (p < 0.001).
|
25312513 |
2015 |
|
rs775743629
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These data underscore the importance of TP53 R72P and MDM2 SNP309 SNPs in MDS, and provide a novel scoring system independent of IPSS that is predictive for disease outcome.
|
26416416 |
2015 |
|
rs2308321
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two non-synonymous SNPs present in the methylguanine methyltransferase (MGMT) gene, in complete linkage disequilibrium, were significantly associated with t-MDS: rs2308321 and rs2308327, with a raw p value of 7.4 × 10(-5) and a corrected p value after Benjamini-Hochberg correction of 0.014.
|
24238921 |
2014 |
|
rs2308327
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two non-synonymous SNPs present in the methylguanine methyltransferase (MGMT) gene, in complete linkage disequilibrium, were significantly associated with t-MDS: rs2308321 and rs2308327, with a raw p value of 7.4 × 10(-5) and a corrected p value after Benjamini-Hochberg correction of 0.014.
|
24238921 |
2014 |
|
rs4553808
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We tested the hypothesis that SNP rs4553808 is associated with RFS, OS, nonrelapse mortality (NRM) and the cumulative incidence of acute graft-versus-host disease (GVHD) and chronic GVHD in adults with acute myeloid leukemia and advanced myelodysplastic syndrome undergoing a first 8/8 or 7/8 HLA-matched unrelated donor HSCT.
|
24631737 |
2014 |
|
rs893810317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, we conducted whole-genome sequencing on a patient with a germline GATA-2 heterozygous mutation (c. 988 C > T; p. R330X), who had a history suggestive of immunodeficiency and evolved into MDS/AML.
|
24782121 |
2014 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, MDR-1 C3435T may have a protective effect against MDS progression because the expected lower expression of P-glycoprotein would lead to a higher degree of cell death.
|
23684483 |
2013 |
|
rs2072671
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The effect of CDA SNP A79C and gender on CDA expression, enzyme activity, and drug pharmacokinetics/pharmacodynamics was examined in mice and humans, and the impact on overall survival (OS) was evaluated in 5-azacytidine/decitabine-treated patients with MDS (n = 90) and cytarabine-treated patients with acute myeloid leukemia (AML) (n = 76).
|
23287564 |
2013 |
|
rs587779821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Quantitative mutation analysis showed higher levels of mutant KIT D816V in SM-CMML and SM-MDS than in pure SM (P < 0.001).
|
23440662 |
2013 |
|
rs1470755915
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MDS was unrelated to the genotype and allele frequencies of c.516G>T SNP in CYP2B6.
|
20878158 |
2011 |
|
rs3745274
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MDS was unrelated to the genotype and allele frequencies of c.516G>T SNP in CYP2B6.
|
20878158 |
2011 |